IFP Advisors’s Relmada Therapeutics RLMD Stock Holding History

IFP Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2	Closed	-$1K	–	4229
2022 Q4	$1K	Hold	2	–	–	﹤0.01%	4457
2022 Q3	$1K	Buy	+2	New	+$55	﹤0.01%	4662

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

IFP Advisors's RLMD Position: Q1 2023 in Review

IFP Advisors sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 2 shares — an estimated $1K sold.

IFP Advisors first reported a position in RLMD in Q3 2022 and held it in 2 quarters. The position peaked at $1K in Q4 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

IFP Advisors reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
IFP Advisors sold 2 Relmada Therapeutics shares in Q1 2023, an estimated $1K.
IFP Advisors first reported a position in Relmada Therapeutics in Q3 2022 and held it in 2 quarters.
IFP Advisors's Relmada Therapeutics position peaked at $1K in Q4 2022.
91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on IFP Advisors's 13F filing for Q1 2023, filed 18 Apr 2023.